Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 9/2008

01-09-2008 | Meeting Report

Second international conference on cancer vaccines/adjuvants/delivery for the next decade (CVADD): Heidelberg, Germany, 10–12 October 2007

Authors: V. Schirrmacher, P. Beckhove, P. Fournier, V. Umansky

Published in: Cancer Immunology, Immunotherapy | Issue 9/2008

Login to get access

Excerpt

The second international conference on “Cancer Vaccines/Adjuvants and Delivery”, CVADD 2007 was organized at the German Cancer Research Center (DKFZ), Heidelberg, Germany. The main aims were to review the state of the art of cancer vaccination with special attention to clinical application in cancer patients. This report provides a short overview of novel concepts, strategies, and clinical developments in the field following the first CVADD congress (Lisbon, Portugal, 2005). About 180 participants from academia and pharma companies were attracted by the scientific program that consisted of keynote lectures and presentations from 50 international experts. Chairman of the symposium was V. Schirrmacher who was supported by an International Scientific Advisory Board and a local organizing committee. Good memories may remain not only from the lively discussions of 11 scientific sessions and 40 posters, but also from the beauty of Heidelberg in autumn colors and the social evening in the Altstadt (Kulturbrauerei) with local food, drinks and music. The conference bags contained a timely issue of “Vaccine” (Vol. 25, Suppl. 2, 27 Sept. 2007), celebrating 25 years of publication. The topic “Therapeutic Vaccines for Cancer” of this issue includes eight reviews from experts in the field. …
Metadata
Title
Second international conference on cancer vaccines/adjuvants/delivery for the next decade (CVADD): Heidelberg, Germany, 10–12 October 2007
Authors
V. Schirrmacher
P. Beckhove
P. Fournier
V. Umansky
Publication date
01-09-2008
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 9/2008
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-008-0470-0

Other articles of this Issue 9/2008

Cancer Immunology, Immunotherapy 9/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine